FDA Approves Subcutaneous Version of Merck's Keytruda

The U.S. Food and Drug Administration has approved Merck's Keytruda Qlex, a subcutaneous formulation of the cancer drug pembrolizumab, for use in adults across most solid tumor indications. Announced on September 19, 2025, this new injectable version offers a quicker administration time compared to the traditional intravenous method, potentially enhancing patient convenience and access to treatment. The approval highlights efforts to innovate drug delivery in oncology amid growing demands for efficient therapies.

Pfizer stock rises after aligning with Trump on drug pricing

1. Oktober 2025 Von KI berichtet

Pfizer's shares climbed on Monday after the company expressed support for former President Donald Trump's proposal to allow imports of lower-priced drugs from Canada. This stance marks a shift for the pharmaceutical giant, which has historically opposed such measures. The move comes amid ongoing debates over U.S. drug costs.

Lawsuits claim Tylenol use in pregnancy causes autism

2. Oktober 2025 Von KI berichtet

More than 100 lawsuits have been filed against acetaminophen manufacturers, including Johnson & Johnson, alleging that the drug's use during pregnancy increases the risk of autism and ADHD in children. These legal actions stem from scientific studies showing associations between prenatal exposure and neurodevelopmental disorders. The cases highlight growing concerns over the safety of a widely used pain reliever.

Ende des Patentschutzes für Abnehmspritzen begünstigt Patienten

Der Patentschutz für das Wirkstoff Semaglutid in Abnehmspritzen wie Ozempic und Wegovy läuft in Europa aus. Das ermöglicht den Markteintritt günstiger Generika und könnte die hohen Preise senken. Patienten mit Adipositas profitieren von besserer Verfügbarkeit.